https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-26 / N. Engl. J. Med. 2018 07;379(2):150-161
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-26 / N. Engl. J. Med. 2018 07;379(2):150-1612018-06-26 00:00:002019-02-15 09:00:21Recurrent Glioblastoma Treated with Recombinant Poliovirus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-26 / N. Engl. J. Med. 2018 07;379(2):194-196
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-26 / N. Engl. J. Med. 2018 07;379(2):194-1962018-06-26 00:00:002019-02-15 09:23:06Exploiting Viruses to Treat Diseases
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-19 / Clin. Cancer Res. 2018 Oct;24(19):4900-4912
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-19 / Clin. Cancer Res. 2018 Oct;24(19):4900-49122018-06-19 00:00:002018-06-19 00:00:00Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-19 / Oncotarget 2018 Jun;9(47):28702-28716
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-19 / Oncotarget 2018 Jun;9(47):28702-287162018-06-19 00:00:002019-02-15 08:36:18Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-18 / Cancer Cell Int. 2018;18:85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-18 / Cancer Cell Int. 2018;18:852018-06-18 00:00:002019-02-15 08:46:17Targeting dendritic cells in pancreatic ductal adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-15 / Rep Pract Oncol Radiother 2018 Nov-Dec;23(6):595-603
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-15 / Rep Pract Oncol Radiother 2018 Nov-Dec;23(6):595-6032018-06-15 00:00:002019-03-27 10:40:07Hyperthermia in cervical cancer – current status
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
root
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
root2018-06-12 18:49:482019-02-10 11:02:26Zwischenergebnisse zur Anwendung von Dendritischen Zellen beim Glioblastom von Dr. Marnix Bosch
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)2018-06-04 11:43:522019-07-17 11:44:13Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-04 / Clin Transl Oncol 2018 Dec;20(12):1502-1521
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-04 / Clin Transl Oncol 2018 Dec;20(12):1502-15212018-06-04 11:14:362019-09-30 11:27:48New physical approaches to treat cancer stem cells: a review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 5509)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 5509)2018-06-03 10:28:302019-07-17 11:18:19Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial.
